Article info
PDFNew Devices and Techniques
Preclinical safety and efficacy evaluation of the Pipeline Vantage Embolization Device with Shield Technology
- Correspondence to Dr Gaurav Girdhar, Neurovascular, Medtronic plc, Irvine, CA 92617, USA; gaurav.girdhar{at}medtronic.com
Citation
Preclinical safety and efficacy evaluation of the Pipeline Vantage Embolization Device with Shield Technology
Publication history
- Received March 19, 2020
- Revised May 5, 2020
- Accepted May 9, 2020
- First published June 2, 2020.
Online issue publication
September 14, 2020
Article Versions
- Previous version (2 June 2020).
- Previous version (27 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.